STB-C017 / Syntekabio - LARVOL DELTA

Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway. (PubMed, Oncoimmunology) - "An orally available lead compound, STB-C017 (designated hereafter as STB), effectively inhibited the enzymatic and cellular activity of IDO and TDO in vitro...Notably, STB-based combination immunotherapy elicited the most potent anti-tumor efficacy through concurrent treatment with immune checkpoint inhibitors, leading to complete tumor regression and long-term overall survival. Our study demonstrated that a novel Kyn pathway regulator derived using deep learning technology can activate T cell immunity and potentiate immune checkpoint blockade by overcoming an immunosuppressive TME."

IO biomarker • Journal • Immune Modulation • Inflammation • Oncology • CD8